Skip to main content

Table 1 Exploratory biomarker analysis of IMpassion 130

From: Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy)

Biomarker Number of subjects HR PFS
A + nP vs P + nP
mPFS HR OS
A + nP vs P + nP
mOS
PD-L1 immune cell expression ≥ 1% and < 5% (low) 243/902(26.9%) 0.61 (95% CI 0.46–0.80)
p < 0.005
7.4 mo 0.68 (95% CI 0.48–0.94)
p = 0.02
22.6 mo
PD-L1 immune cell expression ≥ 5% (high) 125/902 (13.9%) 0.71 (95% CI 0.48–1.05)
p = 0.09
9.3 mo 0.76 (95% CI 0.46–1.26)
p = 0.29
28.9 mo
  1. A total of 902 patients were enrolled and randomized equally to receive either A + nP or P + nP. 40.8% of patient enrolled in the trial were PD-L1 immune cell-positive, defined as PD-L1-positive immune cells occupying at least 1% of the tumor area as determined by the Ventana SP142 assay. Data from Emens JNCI 2021
  2. HR hazard ratio, A atezolizumab, nP nab-paclitaxel, P placebo, PFS progression-free survival, mPFS median progression-free survival, OS overall survival, mOS median overall survival, PD-L1 programmed death ligand-1, CI confidence interval, mo months